Karachi: Liven Pharma Limited has disclosed recent share transactions by an executive director, as per regulations set by the Pakistan Stock Exchange. The announcement, dated July 14, 2026, detailed the share dealings of Executive Director Kaashif Hussain Siddique, involving two separate sales.

On April 17, 2026, Mr. Siddique executed a sale of 32,001 shares at a rate of 42.71 per share. This transaction was conducted in the CDC Ready market, resulting in a cumulative shareholding of 48.99 million shares, maintaining a holding percentage at 43.33%.

A subsequent sale was completed on June 15, 2026, where Mr. Siddique sold an additional 10,000 shares at a rate of 40.50 per share. Post this transaction, his cumulative shareholding stood at 48.99 million shares, with no change in the cumulative percentage, remaining at 43.33%.

According to information available from the Pakistan Stock Exchange (PSX), these transactions by Mr. Siddique are noteworthy in the context of Liven Pharma's market activity. The company's shares have shown significant movement in recent trading sessions.

The declared transactions reflect Liven Pharma's adherence to PSX's disclosure requirements under regulation 5.6.4, ensuring transparency in executive and substantial shareholder dealings. The pharmaceutical company continues to be monitored closely by market analysts and investors within the competitive healthcare sector.